ivosidenib

Independent reference data for ivosidenib (CAS 1448347-49-6), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor approved for use in the US and Europe. It is indicated for the treatment of patients with a susceptible IDH1 mutation with: - **Newly Diagnosed Acute Myeloid Leukemia (AML)** in combination [azacitidine] or as monotherapy for the treatment of newly diagnosed AML in adults who have comorbidities that preclude the use of intensive induction chemotherapy. this indication is reserved for adults 75 years or older in the US. - **Relapsed or refractory AML** inIvosidenib is an orally available small molecule inhibitor of mutated isocitrate dehydrogenase-1 that is used as an antineoplastic agent in the treatment of adults of acute myelogenous leukemia (AML). Ivosidenib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to be the cause of rare instances of clinically apparent acute liver injury.

Synonyms and trade names

Ivosidenib; 1448347-49-6; Tibsovo; AG-120; AG120; Q2PCN8MAM6; ivosidenibum; CHEBI:145430; DTXSID801027928; RefChem:57058; L01XX62; DTXCID801513494; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; RG120

GHS hazard classification

Reported hazard statements	H302 (50%), H360 (50%), H361 (25%), H372 (25%), H373 (50%)

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

H360 (50%): May damage fertility or the unborn child [Danger Reproductive toxicity]

What the public record says

ivosidenib · CAS 1448347-49-6 · C28H22ClF3N6O3. UNII Q2PCN8MAM6. Solubility: <1 mg/mL.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.